EGFR intron 1 polymorphism in Asian populations and its correlation with EGFR gene expression and amplification in breast tumor tissues

Cancer Biology and Therapy

Volumn 5, Issue 11, 2006, Pages 1445-1449

  Zhou, Qingyu ^a   Yin, Bun Cheung ^b   Jada, Srinivasa Rao ^a   Wan, Teck Lim ^a   Kuo, Wen Lin ^c   Gray, Joe W ^c   Lee, Ann S G ^a   Chowbay, Balram ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Asian population; Breast cancer; CA dinucleotide repeats; EGFR; Polymorphism; RT PCR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; ASIAN; BREAST TUMOR; CAUCASIAN; CHINESE; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DINUCLEOTIDE REPEAT; DNA POLYMORPHISM; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; HEREDITY; HUMAN; HUMAN TISSUE; HYPOTHESIS; INDIAN; INTRON; MALAYSIA; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

EID: 33846979783     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.11.3457     Document Type: Article

References (24)

1. Schlessinger J. Cell signalling by receptor tyrosine kinases. Cell 2000; 103:211-25.
2. Simon MA. Receptor tyrosine kinases: Specific outcomes from general signals. Cell 2000; 103:13-5.
3. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82:241-50.
4. Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW. Preferential inactivation of the p53 tumour suppressor pathway and lack of EGFR amplification distinguish de novo high grade paediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 2000; 10:249-59.
5. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERBB2, ERBB3) in colorectal adenocarcinomas and adenomas. Tumor Biol 2000; 21:105-15.
6. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol-Haematol 1995; 19:183-232.
7. Nicholson RI, Gee JMW, Barrow D, Pamment JS, Knowlden JM, McClelland R. Endocrine resistance in breast cancer can involve a switch towards EGFR signalling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839. Washington DC: Proc AACR-NCI-EORTC Meeting, 1999.
8. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999; 5:2884-90.
9. Chen Z, Ke LD, Yuan XH, Adler-Storthz K. Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells. Anticancer Res 2000; 20:899-902.
10. Gebhardt F, Zankers KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999; 274:13176-180.
11. Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, Simon R, Lelle R, Boecker W, Brandt B. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000; 60:854-57.
12. Liu W, Innocenti F, Chen P, Das S, Cook Jr EH, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron I polymorphism. Clin Cancer Res 2003; 9:1009-12.
13. Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S, Carroll P, Kuo WL, Pinkel D, Albertson D, Cordon-Cardo C, Jain AN, Waldman FM. Array- based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003; 63:2872-80.
14. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, Chen C, Polikoff D, Jain AN, Pinkel D, Albertson DG, Jablons DM, Gray JW. Genomic copy number analysis of nonsmall cell lung cancer using array comparative genomic hybridization: Implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002; 62:3636-40.
15. Sham P. Statistics in Human Genetics. London: Arnold, 1998.
16. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumour effects in athymic mice. J Pharmacol Exp Ther 1999; 291:739-48.
17. Lichtner RB, Menrad A, Sommer A, Klar U, Schneider MR. Signalling inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001; 61:5790-95.
18. Fukuoka M, Yano S, Giaccone G. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced nonsmall-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21:198a.
19. Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. Absence of EGFR mutation in the kinase domain in common human cancers besides nonsmall cell lung cancer. Int J Cancer 2005; 113:510-11.
20. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005; 6:279-86.
21. Amador ML, Oppenheimer D, Perea S, Maitra A, Cusati G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004; 64:9139-43.
22. Baselga J, Averbuch SD. ZD1839 (Iressa) as an anticancer agent. Drugs 2000; 60:33-40.
23. Baselga J. New therapeutic agents targetting the epidermal growth factor receptor. J Clin Oncol 2000; 18:54S-59S.
24. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110-24.